Gapping down
In reaction to disappointing earnings/guidance: AKS -8.6%, YOKU -4.8%, TIF -3.3%, ZFGN -0.9%, CERU -0.6%, SBLK -0.6%, CHL -0.5%
M&A news: MAC -8.6% (following final offer from SPG for $95.50 per MAC share, up from prior $91 offer; move in stock suggests expectations that offer likely to be rejected)
Other news: BIOD -8.7% (filed for $30 mln offering of common stock), THRX -7.3% (FDA Advisory Committee votes against safety and efficacy of BREO ELLIPTA (fluticasone furoate/vilanterol) for the treatment of asthma in children 12-17 years of age), ACUR -3.4% (disclosed that it was afforded an additional 180 calendar day period to regain compliance with the minimum bid price requirement of $1.00 per share), CRMD -2.6% (announces that the registration statements for the shares of its common stock underlying its publicly traded warrants have both been declared effective by the SEC), MTGE -2.3% (cuts dividend; also downgraded at Wunderlick)
Analyst comments: ERIC -1% (downgraded to Equal-Weight from Overweight at Morgan Stanley), DATA -1% (downgraded to Neutral at Mizuho), VNCE -0.8% (downgraded to Neutral from Overweight at Piper Jaffray)
In reaction to disappointing earnings/guidance: AKS -8.6%, YOKU -4.8%, TIF -3.3%, ZFGN -0.9%, CERU -0.6%, SBLK -0.6%, CHL -0.5%
M&A news: MAC -8.6% (following final offer from SPG for $95.50 per MAC share, up from prior $91 offer; move in stock suggests expectations that offer likely to be rejected)
Other news: BIOD -8.7% (filed for $30 mln offering of common stock), THRX -7.3% (FDA Advisory Committee votes against safety and efficacy of BREO ELLIPTA (fluticasone furoate/vilanterol) for the treatment of asthma in children 12-17 years of age), ACUR -3.4% (disclosed that it was afforded an additional 180 calendar day period to regain compliance with the minimum bid price requirement of $1.00 per share), CRMD -2.6% (announces that the registration statements for the shares of its common stock underlying its publicly traded warrants have both been declared effective by the SEC), MTGE -2.3% (cuts dividend; also downgraded at Wunderlick)
Analyst comments: ERIC -1% (downgraded to Equal-Weight from Overweight at Morgan Stanley), DATA -1% (downgraded to Neutral at Mizuho), VNCE -0.8% (downgraded to Neutral from Overweight at Piper Jaffray)